Medical Advocates

HCV Infection/Disease

 
Drugs
General Reports
HCV Protease Inhibitors

Amantadine
Atazanavir

Daclatasvir
Erythropoietin

Interferons
Ledipasvir
Lopinavir
Mericitabine

 

Nevirapine

NS5A Inhibitors.
Peg Interferon-Alfa-2a 
Peg Interferon-Alfa-2b  
Raltegravir
Ribavirin

Rifampin
Rituximab
Sofosbuvir
Statins
Steroid Therapy
Tacrolimus
Alternative Therapies
Investigational Therapies
Post-Transplant Drugs



 

HCV Main Page Main New/Newsworthy    Home Page    

Last Update:  October 19, 2014
 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
 

     Journal Papers, Abstracts, and Commentaries

 
Spontaneous clearance of hepatitis C virus in a patient co-infected with hepatitis C virus and human immunodeficiency virus: a case report.
Kaung A, Sundaram V, Tran TT.

J Gastrointestin Liver Dis
. 2014 Sep;23(3):325-7.
Abstract.

Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.
Applegate TL, Gaudieri S, Plauzolles A,  et al
Antivir Ther
. 2014 Aug 8.
Abstract

Antiviral treatment of hepatitis C.
Feeney ER, Chung RT.
BMJ. 2014 Jul 7;349:g3308.
Abstract

Update on hepatitis C virus resistance to direct-acting antiviral agents.
Poveda E, Wyles DL, Mena A,  et al
Antiviral Res. 2014 Jun 6.
Abstract

FULL-TEXT ARTICLE
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.
Xiao F, Fofana I, Thumann C, Mailly L, et al
Gut. 2014 May 21.
Paper

HCV direct-acting antiviral agents: the best interferon-free combinations.
Schinazi R, Halfon P, Marcellin P, Asselah T.
Liver Int
. 2014 Feb;34 Suppl 1:69-78.

Minimum costs for producing Hepatitis C Direct Acting Antivirals, for use in large-scale treatment access programs in developing countries
Hill A, Khoo S, Fortunak J, et al

Clin Infect Dis. 2014 Jan 6.
Abstract

FULL-TEXT ARTICLE
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.
Zhu Y, Chen S.
World J Gastroenterol. 2013 Dec 21;19(47):8963-8973.
Paper

Impact of Interferon Free Regimens on Clinical and Cost Outcomes for Chronic Hepatitis C Genotype 1 Patients.
Younossi ZM, Singer ME, Mir HM,  et al
J Hepatol
. 2013 Nov 19.
Abstract

Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis.
Zhou H, Luo H, Xiao S,  et al
Eur J Clin Microbiol Infect Dis. 2013 Nov 6.
Abstract

Interferon-Free Regimens for Hepatitis C: Combine and Conquer.
Martel-Laferrière V, Bichoupan K, Dieterich DT.
BioDrugs
. 2013 Oct 30
.
Abstract

The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C virus.
Maasoumy B, Port K, Calle Serrano B, et al
Aliment Pharmacol Ther. 2013 Oct 16
Abstract

Novel Therapeutic Approaches for Hepatitis C.
Au JS, Pockros PJ.
Clin Pharmacol Ther. 2013 Oct 14.
Abstract


Is there sufficient evidence to recommend antiviral therapy in hepatitis C?
v
an der Meer AJ, Wedemeyer H, Feld JJ,  et al
J Hepatol
. 2013 Aug 20.
Abstract

Drug-drug interactions during antiviral therapy for chronic hepatitis C.
Kiser JJ, Burton JR Jr, Everson GT
Nat Rev Gastroenterol Hepatol. 2013 Jul 2.
Abstract

Cost-Effectiveness Analysis of Direct-Acting Antiviral Therapy for Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Infection in the Veterans Health Administration.
Chan K, Lai MN, Groessl EJ,  et al
Clin Gastroenterol Hepatol
. 2013 May 22.
Abstract

A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.
Bruce RD, Moody DE, Altice FL,  et al
Expert Rev Clin Pharmacol
. 2013 May;6(3):249-69.
Abstract

Earlier Sustained Virologic Response Endpoints for Regulatory Approval and Dose Selection of Hepatitis C Therapies.
Chen J, Florian J, Carter W, Fleischer RD, et al
Gastroenterology
. 2013 Mar 4.
Abstract

Antiviral resistance and direct-acting antiviral agents for HCV.
Aloia AL, Locarnini S, Beard MR.
Antivir Ther. 2012;17(6 Pt B):1147-62.
Abstract

Future perspectives: towards interferon-free regimens for HCV.
Gane E.
Antivir Ther
. 2012;17(6 Pt B):1201-10.
Abstract

Highly active anti-hepatitis C therapy: seven lessons from HIV.
Thomas DL.
Antivir Ther
. 2012;17(6 Pt B):1183-8.
Abstract

HCV Variants with Decreased Sensitivity to Direct Acting Antivirals Were Rarely Observed in DAA-Naive Patients Prior to Treatment.
Bartels DJ, Sullivan JC, Zhang EZ, et al 
J Virol
. 2012 Nov 14.
Abstract

The changing face of hepatitis C in the new era of direct-acting antivirals.
Soriano V, Labarga P, Fernández-Montero JV,  et al
Antiviral Res
. 2012 Nov 9.
Abstract

FULL-TEXT PDF ARTICLE
New therapeutic options for HCV infection in the monoclonal antibody era.
Sautto GA, Diotti RA, Clementi M.
New Microbiol. 2012 Oct;35(4):387-97.

Abstract

Pharmacokinetics of new oral hepatitis C antiviral drugs.
Vispo E, Barreiro P, Soriano V.
Expert Opin Drug Metab Toxicol. 2012 Oct 25.
Abstract

New hepatitis C virus drug discovery strategies and model systems.
Hussain S, Barretto N, Uprichard SL.

Expert Opin Drug Discov
. 2012 Sep;7(9):849-59.
Abstract

Current and emerging antiviral treatments for hepatitis C infection.
Doyle JS, Aspinall E, Liew D, et al
Br J Clin Pharmacol. 2012 Aug 13.
Abstract

New antiviral therapies in the management of HCV infection.
Farnik H, Zeuzem S.

Antivir Ther
. 2012 May 25. 
Abstract

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
Barritt AS 4th, Fried MW
Gastroenterology. 2012 May;142(6):1314-1323.
Abstract

FULL-TEXT ARTICLE
New antiviral agents for hepatitis C.
Pawlotsky JM.
F1000 Biol Rep. 2012;4:5..
Paper

Antiviral Drugs and the Treatment of Hepatitis C.
Jalali Z, Rockstroh JK.
Curr HIV/AIDS Rep. 2012 Feb 22
Abstract

Antiviral strategies in hepatitis C virus infection.
Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.
J Hepatol. 2012;56 Suppl:S88-S100
Abstract

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
Asselah T, Marcellin P.
Liver Int.2012 Feb;32 Suppl 1:88-102. .
Abstract

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P, Sarrazin C.
Liver Int. 2012 Feb;32 Suppl 1:79-87.
.
Abstract

New targets for antiviral therapy of chronic hepatitis C.
Bühler S, Bartenschlager R.
Liver Int. 2012 Feb;32 Suppl 1:9-16.
Abstract

FULL-TEXT ARTICLE
The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors.
Kwo PY, Vinayek R.
Gut Liver. 2011 Dec;5(4):406-17
Paper

Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C
in HIV-Infected Persons.
Thomas DL, Bartlett JG, Peters MG, et al
Clin Infect Dis. 2011 Dec 14
Abstract

Recent advance in antiviral drugs for hepatitis C.
Liu J, Shi S, Zhuang H, Luo G.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Nov;36(11):1025-36.
Abstract

Mechanisms Involved in the Development of Chronic Hepatitis C as Potential Targets of Antiviral Therapy.
Jackowiak P, Figlerowicz M, Kurzyńska-Kokorniak A, Figlerowicz M.
Curr Pharm Biotechnol
. 2011 Sep 9.
Abstract

Oral combination therapy: Future hepatitis C virus treatment?
Hézode C.
J Hepatol. 2011 May
Abstract

Current drug discovery strategies for treatment of hepatitis C virus infection.
Cheng KC, Gupta S, Wang H,  et al
J Pharm Pharmacol. 2011 Jul;63(7):883-92.
Abstract

Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
Masarone M, Persico M.
Expert Rev Anti Infect Ther. 2011 May;9(5):535-43..
Abstract

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.
Pearlman BL, Traub N.
Clin Infect Dis. 2011 Apr;52(7):889-900
Abstract

Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Gluhovschi C, Gadalean F, Kaycsa A, et al
Immunopharmacol Immunotoxicol. 2011 Feb 14
Abstract

Hepatitis C virus Resistance to Protease Inhibitors.
Halfon P, Locarnini S.
J Hepatol
. 2011 Jan 29.
Abstract

Mixing the right hepatitis C inhibitor cocktail.
Gelman MA, Glenn JS.
Trends Mol Med
. 2010 Nov 22.
Abstract

Susceptibility of Treatment-Naive HCV Clinical Isolates to HCV Protease Inhibitors.
Bae A, Sun SC, Qi X, et al
Antimicrob Agents Chemother
. 2010 Sep 20
Abstract

Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial.
Morasco BJ, Loftis JM, Indest DW,
 et  al
Psychosomatics
. 2010 Sep;51(5):401-8.
Abstract

Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success.
Cooper C.
Can J Gastroenterol. 2010 Jun;24(6):385-90
Abstract

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
Seden K, Back D, Khoo S.
J Antimicrob Chemother
. 2010 Mar 23
Abstract


Atazanavir
 

    Conference Reports, Abstracts, and Posters
 
  Atazanavir and ritonavir pharmacokinetics with telaprevir-based HCV treatment (ANRSHC26)
A. Barrail-Tran, J. Braun, C. Vincent, et al
(XX International AIDS Conference)
Abstract

Daclatasvir
 

      Journal Papers, Abstracts, and Commentaries
 
  Drug-Induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir.
Fujii Y, Uchida Y, Mochida S.
Hepatology
. 2014 Oct 12.
Abstract

Daclatasvir plus Peginterferon and Ribavirin is Non-inferior to Peginterferon and Ribavirin Alone, and Reduces Duration of Treatment for HCV Genotype 2 or 3 Infection.
Dore GJ, Lawitz E, Hézode C,  et al
Gastroenterology. 2014 Oct 10
Abstract

A WEEK-IN-REVEW FEATURED REPORT
Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.
Aghemo A, De Francesco R.
Gut. 2014 Sep 5.
Abstract

Daclatasvir + Asunaprevir: First Global Approval.
Poole RM.
Drugs. 2014 Aug 13

Abstract

A WEEK-IN-REVEW FEATURED REPORT
The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus.
Eley T, Sevinsky H, Huang SP, et al

Clin Drug Investig
. 2014 Aug 13.

Abstract

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M, Pol S, Jacobson IM,  et al
Lancet. 2014 Jul 26.

Abstract

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.
Hézode C, Hirschfield GM, Ghesquiere Wm et al
Gut
. 2014 Jul 30. pii: gutjnl-2014-307498.
Abstract

A WEEK-IN-REVEW FEATURED REPORT
Efficacy of daclatasvir in hepatitis C virus.
I
zumi N.
Expert Rev Anti Infect Ther
. 2014 Jul 25:1-7.

Abstract

Daclatasvir for the treatment of hepatitis C virus infection
Adler H, Lambert JS.
Expert Rev Gastroenterol Hepatol. 2014 May 31:1-14

Abstract

HCV Therapy With Daclatasvir, PEG-IFN, and RBV After Boceprevir-Based Therapy Failure Post-Liver Transplantation in Hyper-IgM Syndrome.
Reddy KR, Wirjosemito A, Pavri TM, Sinese L.
Transplantation
. 2014 Apr 27;97(8):e47-8
Abstract

Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect."
Belema M, Meanwell NA.
J Med Chem
. 2014 Apr 21
Abstract

FULL-TEXT ARTICLE
Daclatasvir plus sofosbuvir for HCV infection.
Sulkowski MS, Jacobson IM, Nelson DR.
N Engl J Med
. 2014 Apr 17;370(16):1560-`1.
Paper

A WEEK-IN REVIEW FEATURED REPORT
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
Kumada H, Suzuki Y, Ikeda K et al
Hepatology. 2014 Mar 6.

Abstract

A WEEK-IN-REVIEW FEATURED REPORT

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection.
Everson GT, Sims KD, Rodriguez-Torres M,  et al
Gastroenterology
. 2014 Feb;146(2):420-9.
Abstract

Ultra deep sequencing study of HCV genotype 1 in chronic hepatitis patients treated with daclatasvir, peg-interferon and ribavirin.
Murakami E, Imamura M, Hayes CN, et al
Antimicrob Agents Chemothe
r
. 2014 Jan 27
Abstract

Virologic escape in HCV genotype 1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
McPhee F, Hernandez D, Zhou N,  et al
Antivir Ther. 2014 Jan 22.

Abstract

A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
Suzuki F, Toyota J, Ikeda K,  et al
Antivir Ther
. 2014 Jan 22.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Sulkowski MS, Gardiner DF, Rodriguez-Torres M,  et al
N Engl J Med
. 2014 Jan 16;370(3):211
Abstract

Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A.
Gentile I, Borgia F, Coppola N, et al
Curr Med Chem
. 2013 Dec 28.
Abstract

Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
Bifano M, Sevinsky H, Hwang C,  et al
Antivir Ther
. 2013 Dec 17
Abstract

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection.
Everson GT, Sims KD, Rodriguez-Torres M,  et al
Gastroenterology
. 2013 Oct 30.
Abstract

Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration.
Ke R, Loverdo C, Qi H,  et al
J Antimicrob Chemother
. 2013 Oct 29
Abstract

A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir.
O'Boyle DR 2nd, Nower PT, Sun JH, et al
J Virol Methods. 2013 Oct;193(1):68-76

Abstract

FULL-TEXT ARTICLE

Daclatasvir: potential role in hepatitis C.
Lee C.
Drug Des Devel Ther
. 2013 Oct 16;7:1223-33
Paper

Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Bifano M, Hwang C, Oosterhuis B,
Antivir Ther. 2013 Aug 20

Abstract

Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus
Aghemo A, Colombo M.
Gastroenterology. 2013 Jul;145(1):247-9

Abstract

The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate.
Guedj J, Dahari H, Uprichard SL, Perelson AS.
Expert Rev Gastroenterol Hepatol
. 2013 Jul;7(5):397-9
Abstract

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.
Fontana RJ, Hughes EA, Bifano M,  et al
Am J Transplant
. 2013 Jun;13(6):1601-5.
Abstract

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
Suzuki Y, Ikeda K, Suzuki F,  et al
J Hepatol
. 2013 Apr;58(4):655-62.
Abstract

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F, Hernandez D, Yu F,  et al
Hepatology. 2013 Mar 15.
Abstract

FULL-TEXT ARTICLE
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
Guedj J, Dahari H, Rong L,  et al
Proc Natl Acad Sci U S A
. 2013 Mar 5;110(10):3991-6.
Paper

   Videos

A New Way to HIV Functional Cure: HIV Pathogenesis Sabotage with Dolutegravir

Erythropoietin
 

     Journal Papers, Abstracts, and Commentaries
 
 

Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin.
Sherman M, Cohen L, Cooper MA, et al 
Can J Gastroenterol.
2006 Jul;20(7):479-85.

Abstract

Epoetin alfa for the Treatment of Combination Therapy-Induced Hemolytic Anemia in Patients Infected with Hepatitis C Virus.
Rivkin AM, Chawla S. 
Pharmacotherapy. 2005 Jun;25(6):862-7
Abstract 

Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
Durante Mangoni E, Marrone A, Saviano D
Antivir Ther. 2003 Feb;8(1):57-63
Abstract

Ledipasvir
 

      Journal Papers, Abstracts, and Commentaries
 
 

Lack of a Clinically Important Pharmacokinetic Interaction Between Sofosbuvir or Ledipasvir and Hormonal Oral Contraceptives Norgestimate/Ethinyl Estradiol in HCV-Uninfected Female Subjects.
German P, Moorehead L, Pang PS, et al
J Clin Pharmacol
. 2014 Jun 13
Abstract

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Lawitz E, Poordad FF, Pang PS, et al
Lancet. 2013 Nov 1.
Abstract


Lopinavir
 

    Conference Reports, Abstracts, and Posters
 
  POSTER
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV coinfected patients starting anti-HCV treatment:
final results of a randomised, proof-of- principle clinical trial (KAMON 2 Study)

H. Hasson, L. Galli, G. Gallotta
(6th IAS Conference)

Poster      Abstract

Mericitabine
 

      Journal Papers, Abstracts, and Commentaries
 
  In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir.
Tong X, Le Pogam S, Li L,et al
J Infect Dis
. 2013 Nov 11
Abstract

Nevirapine
 

     Journal Papers, Abstracts, and Commentaries
 
  Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens : CD4+ T-Cell Count and Gender in Hepatitis C Seropositive and Seronegative Patients.
Torti C, Costarelli S, De Silvestri A, et al 
Drug Saf.
2007;30(12):1161-9.

Abstract

NS5A Inhibitors
 

     Journal Papers, Abstracts, and Commentaries

  Daclatasvir-like Inhibitors of NS5A Block Early Biogenesis of HCV-induced Membranous Replication Factories, Independent of RNA Replication.
Berger C, Romero-Brey I, Radujkovic D, et al
Gastroenterology. 2014 Jul 18.
Abstract

FULL-TEXT ARTICLE
Approaches to hepatitis C treatment and cure using NS5A inhibitors.

Kohler JJ, Nettles JH, Amblard F,  et al
Infect Drug Resist
. 2014 Mar 5;7:41-56.
Paper


Raltegravir
 

     Journal Papers, Abstracts, and Commentaries
 
 

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
Vispo E, Mena A, Maida I, et al
J Antimicrob Chemother
. 2009 Dec 23

Abstract


Rifampin
 

Rifampin/Pyrazinamide

     Journal Papers, Abstracts, and Commentaries

  Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
Kunimoto D, Warman A, Beckon A,  et al.
Clin Infect Dis. 2003 Jun 15;36(12):E158-61

Abstract
 
Rituximab
 

   Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT ARTICLE
Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection.
Bonilla-Abadía F, Echeverri AF,  et al
Case Report Rheumatol. 2012;2012:923897.
Paper

FULL-TEXT ARTICLE
Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity.
Stamataki Z, Tilakaratne S, Adams DH, McKeating JA.

PLoS One
. 2011;6(9):e25789.
Paper

Rituximab plus Peg-Interferon {alpha} /ribavirin compared to Peg- Interferon {alpha} /ribavirin in Hepatitis C related mixed cryoglobulinemia.
Saadoun D, Resche Rigon M, et al
Blood
. 2010 May
Abstract

Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup
study of thirty-two patients.
Terrier B, Saadoun D, Sène D, et al
Arthritis Rheum
. 2009 Jul 30;60(8):2531-2540.
Abstract

Hepatitis C virus infection and rituximab therapy after renal transplantation.
Fabrizi F, Martin P, Elli A, et al 
Int J Artif Organs.
2007 May;30(5):445-9.

Abstract


Sofosbuvir
 

      News Releases
 
  U.S. Food and Drug Administration Approves Gilead’s Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Gilead
Dec. 6, 2013
News

      Journal Papers, Abstracts, and Commentaries
 

 
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Lawitz E, Poordad F, Brainard DM, et al 
Hepatology. 2014 Oct 16
Abstract

Concordance of Sustained Virologic Response 4, 12, and 24 Weeks Post-Treatment With Sofosbuvir-Containing Regimens for Hepatitis C Virus.
Yoshida EM, Sulkowski MS, Gane EJ,  et al
Hepatology
. 2014 Oct 14
Abstract

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation.
Charlton M, Gane E, Manns MP, et al
Gastroenterology
. 2014 Oct 7.
Abstract

Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection after Liver Transplantation: An Open-Label Study.
Curry MP, Forns X, Chung RT, Terrault NA, et al.
Gastroenterology. 2014 Sep 24
Abstract

Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic HCV, genotype-1 infected patients.
Meissner EG, Lee YJ, Osinusi A,  et al
Hepatology
. 2014 Sep 9
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
CON Sofosbuvir and Ribavirin Use in Wait-Listed Patients with Hepatitis C Should be Selective.
Price JC, Terrault NA.
Liver Int. 2014 Sep 2.
Abstract

Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.
Summers BB, Beavers JW, Klibanov OM.

J Pharm Pharmacol
. 2014 Aug 31.

Abstract

Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in HIV-HCV coinfected patient.
Borentain P, Colson P, Dhiver C,  et al
Antivir Ther. 2014 Aug 8.
Abstract

FULL-TEXT ARTICLE
Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma.
Peixoto RD, Renouf DJ, Gill S,  et al J
Gastrointest Oncol
. 2014 Aug;5(4):259-64
Paper

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Saab S, Gordon SC, Park H,  et al
Aliment Pharmacol Ther
. 2014 Jul 28
Abstract

Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment.
Gentile I, Borgia G.
Evid Based Med. 2014 Jul 15.
Abstract

Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late.
Pellicelli AM, Montalbano M, Lionetti R, et al
Dig Liver Dis. 2014 Jul 2.
Abstract

Sofosbuvir for the treatment of chronic hepatitis C virus infection.
Temesgen Z, Talwani R, Rizza SA.
Drugs Today (Barc). 2014 Jun;50(6):421-434.|
Abstract

Lack of a Clinically Important Pharmacokinetic Interaction Between Sofosbuvir or Ledipasvir and Hormonal Oral Contraceptives Norgestimate/Ethinyl Estradiol in HCV-Uninfected Female Subjects.
German P, Moorehead L, Pang PS, et al
J Clin Pharmacol
. 2014 Jun 13
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection.
Rose L, Bias TE, Mathias CB,  et al
Ann Pharmacother. 2014 May 8
Abstract

FULL-TEXT ARTICLE
Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential.

Stedman C.
Therap Adv Gastroenterol
. 2014 May;7(3):131-140.
Paper

FULL-TEXT ARTICLE
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3.
Zeuzem S, Dusheiko GM, Salupere R, et sl
N Engl J Med. 2014 May 4.
Paper

Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
Sofia MJ.
Antiviral Res. 2014 May 2.
Abstract

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives.
Degasperi E, Aghemo A.

Hepat Med
. 2014 Apr 29;6:25-33
Abstract

Sofosbuvir in the Treatment of Chronic Hepatitis C: New Dog, New Tricks.
Abraham GM, Spooner LM.
Clin Infect Dis. 2014 Apr 18
Abstract

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection.
Afdhal N, Zeuzem S, Kwo P,  et al
N Engl J Med
. 2014 Apr 11.
Abstract

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection.
Afdhal N, Reddy KR, Nelson DR,  et al
N Engl J Med. 2014 Apr 11
Abstract

Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
Younossi ZM, Stepanova M, Nader F,  et al
Hepatology. 2014 Apr 8.
Abstract

FULL-TEXT PDF ARTICLE
[MUST BE DOWNLOADED DIRECTLY FROM SITE)

Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
Gaetano JN.
Drug Healthc Patient Saf. 2014 Mar 31;
Paper

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals.
Hagan LM, Sulkowski MS, Schinazi RF.
Hepatology
. 2014 Mar 28.
Abstract

Hepatitis C virus: Here comes all-oral treatment.
Dugum M, O'Shea R.
Cleve Clin J Med
. 2014 Mar;81(3):159-72.
Abstract

In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors
Mericitabine and Sofosbuvir.

Tong X, Le Pogam S, Li L, et al
J Infect Dis. 2014 Mar;209(5):668-75.

Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.
Koff RS.
Aliment Pharmacol Ther
. 2014 Mar;39(5):478-87
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.
Guedj J, Pang PS, Denning J, Rodriguez-Torres M,  et al
Antivir Ther
. 2014 Jan 24.

Abstract

Sofosbuvir for the treatment of hepatitis C virus.
Asselah T.
Expert Opin Pharmacother
. 2014 Jan;15
Abstract

Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection
Koff RS.
Aliment Pharmacol Ther
. 2014 Jan 6.

Abstract

IFNL4-ΔG Genotype is Associated with Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated with Sofosbuvir and Ribavirin.
Meissner EG, Bon D, Prokunina-Olsson L,  et al
J Infect Dis. 2013 Dec 23.

Abstract

FULL-TEXT ARTICLE

Sofosbuvir has come out of the magic box.
Alavian SM.
Hepat Mon. 2013
16;13(12):e16916.
Paper


Sofosbuvir with ribavirin is safe and effective in hepatitis C genotype 1 with unfavourable pretreatment characteristics.
Ferguson MC.
Evid Based Med
. 2013 Dec 12.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
Rodríguez-Torres M.
Expert Rev Anti Infect Ther
. 2013 Dec;11(12):1269-79.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Effects of Sofosbuvir-based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C.
Younossi ZM, Stepanova M, Henry L,  et al
Clin Gastroenterol Hepatol
. 2013 Dec 5.
Abstract

Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
Rodríguez-Torres M.
Expert Rev Anti Infect Ther
. 2013 Dec;11(12):1269-79.
Abstract

Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir plus the NS5A Inhibitor Ledipasvir or the NS5B Non-nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection.
Gane EJ, Stedman CA, Hyland RH, et al
Gastroenterology
. 2013 Nov 18.
Abstract

In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir.
Tong X, Le Pogam S, Li L,et al
J Infect Dis
. 2013 Nov 11
Abstract

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Lawitz E, Poordad FF, Pang PS, et al
Lancet. 2013 Nov 1.

Abstract

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F, Hernandez D, Yu F,  et al
Hepatology
. 2013 Sep;58(3):902-11
Abstract

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
Osinusi A, Meissner EG, Lee YJ,  et al
JAMA
. 2013 Aug 28;310(8):804-11
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE

Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
Zeng QL, Zhang JY, Zhang Z, et al
World J Gastroenterol
. 2013 Jun 7;19(21):3199-206
Paper

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.
Fontana RJ, Hughes EA, Bifano M, et al
Am J Transplant
. 2013 Jun;13(6
Abstract

Sofosbuvir-Based Antiviral Therapy for Treatment Naïve Hepatitis C Genotypes 1, 2, and 3.
Sharma P.
Gastroenterology
. 2013 May 27.
Abstract

FULL-TEXT ARTICLE
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
Wang C, Sun JH, O'Boyle DR 2nd, et aL
Antimicrob Agents Chemother. 2013 May;57(5):2054-65
Paper

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection:
a randomised, double-blind, phase 2 trial.
Lawitz E, Lalezari JP, Hassanein T,  et al
Lancet Infect Dis
. 2013 May;13(5):401-8.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection.
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M,  et al
N Engl J Med. 2013 Apr 23.
Abstract

FULL-TEXT ARTICLE
Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.
Herbst DA Jr, Reddy KR.
Expert Opin Investig Drugs
. 2013 Apr;22(4):527-36.
Abstract
 

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options.
Jacobson IM, Gordon SC, Kowdley KV,  et al
N Engl J Med
. 2013 Apr 23.
Abstract

A WEEK--IN- REVIEW FEATURED REPORT
Sofosbuvir , a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.
Herbst DA Jr, Reddy KR.
Expert Opin Investig Drugs
. 2013 Mar 1.

Abstract

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised,
multicentre phase 2 trial.
Kowdley KV, Lawitz E, Crespo I,  et al
Lancet. 2013 Mar 14
Abstract

   
 

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
Gane EJ, Stedman CA, Hyland RH,
N Engl J Med
. 2013 Jan 3;368(1):34-44.
Abstract

  Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial.
Rodriguez-Torres M, Lawitz E,  et a;
J Hepatol. 2012 Nov 23.

Abstract
   
 

FULL-TEXT ARTICLE
Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.
Lam AM, Espiritu C, Bansal S, Micolochick S
Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68
Paper

 

Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938.
Chun BK, Du J, Zhang HR,
Nucleosides Nucleotides Nucleic Acids. 2011 Nov;30(11):886-96
Abstract

 

Statins
 

   Journal Papers, Abstracts, and Commentaries
 
  Are statins a viable option for the treatment of infections with the hepatitis C virus?
Verpaalen B, Neyts J, Delang L.
Antiviral Res
. 2014 Mar 5.
.
Abstract

Statin Therapy and Serum Transaminases Among a Cohort of HCV-Infected Veterans.
Henderson LM, Patel S, Giordano TP, et al 
Dig Dis Sci
. 2009 Sep 3.
Abstract


Steroid Therapy
 

 Journal Papers, Abstracts, and Commentaries
 
  Does low-dose prolonged steroid therapy affect the natural history of chronic hepatitis C?
Romero Gutiérrez M, Del Campo Terrón S,  et al
J Med Virol
. 2014 May;86(5):758-64.

Abstract
   

Alternate Therapies
 

     Journal Papers, Abstracts, and Commentaries

 
High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy.
Biermer M, Schlosser B, Fülöp B, et al

J Viral Hepat
. 2012 Aug;19(8):547-53
Abstract

High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure
Estes JD, Stolpman D, Olyaei A 

Arch Surg.
2003 Aug;138(8):852-8.
Abstract

The use of alternative medicine in the treatment of hepatitis C.
Bean P
Am Clin Lab 2002 May;21(4):19-21
Abstract

 

HCV Main Page Main New/Newsworthy    Home Page    

HCV Drugs

.